Navigation Links
5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
Date:6/12/2012

Five additional pharmaceutical companies have joined a National Institutes of Health-led effort to help scientists research promising new treatments for patients. Funding and molecular compound information is available now for the initial phase of the recently unveiled Discovering New Therapeutic Uses for Existing Molecules program. This NIH-industry collaboration will match researchers with 58 compounds to test ideas for new therapeutic uses. Since the launch of the program last month, the total number of compounds the companies are making available has more than doubled.

Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., and Sanofi have joined Pfizer, AstraZeneca, and Eli Lilly and Company in this innovative approach to research.

The NIH's new National Center for Advancing Translational Sciences (NCATS) created the Therapeutics Discovery program to help re-engineer the research pipeline. By crowdsourcing compounds that already have cleared several key steps in the development process, including safety testing in humans, scientists nationwide have the opportunity to contribute their expertise to advancing these resources for new disease therapies.

The eight participating companies will provide their compounds and related data, which were determined by the NIH to meet specific eligibility criteria. For example, each compound must have advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued for business reasons. Preliminary information about the compounds, including mechanism of action, route of administration, and any limitations in use based on safety and tolerability, are available at http://ncats.nih.gov/therapeutics-directory.html.

"Each company participating in this innovative collaboration has made substantial research and development investments to advance these compounds to the point where they can be used in clinical studies," said Kathy L. Hudson, Ph.D., NCATS acting deputy director. "If researchers funded through this effort can demonstrate new uses for the compounds, they could significantly reduce the amount of time it takes to get a treatment to patients in need."

For the pilot phase of the program, in fiscal year 2013, NCATS will provide up to $20 million to fund two- to three-year staged, cooperative agreement research grants. If specific milestones are met, funded researchers will conduct pre-clinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to test whether one of the compounds may be effective against a previously unexplored disease target. The pilot phase also is intended to test the utility of the newly created template agreements by reducing the negotiation time that otherwise could delay the research.


'/>"/>

Contact: Bobbi Gardner
gardnerbw@mail.nih.gov
301-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Nobel laureate to keynote international pharmaceutical conference at URI
2. MSU invention could help pharmaceutical industry save money
3. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
4. Georgia Tech launches HomeLab to help companies evaluate home health technologies
5. Kudos for 3 NJIT Enterprise Development Center high-tech companies
6. New initiative aims to increase mobility for disabled children worldwide
7. National initiative launched to change the way biology departments approach undergraduate education
8. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
9. U.S. Spends Too Little on Public Health Initiatives: Report
10. Program to coordinate regional systems to speed heart attack care
11. Advanced genetic screening method may speed vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the way around ... are in for and they are often worried things won’t go well. More often than ... This year’s Au Pair of the Year winner’s all commented how their Au Pairs have ...
(Date:2/12/2016)... , ... February 12, 2016 , ... The law firm ... and Evangeline Parishes. The purpose of these scholarships is to encourage applicants to ... individuals to seek employment within these two parishes. , “We have available jobs ...
(Date:2/12/2016)... ... , ... Each year, the American Physical Therapy Association (APTA) offers a Combined ... Convention Center. Almost 10,000 physical therapists across the country are expected to attend this ... their chosen field and network with their colleagues. As in years past, HydroWorx ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into ... partners to offer real-time business intelligence (BI) to their small and medium business ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one ... consists of physicians establishing, leading and partnering with ambulatory surgery centers across the United ... Center, also known as an ASC, is a modern health care facility focused on ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... DIEGO and SEOUL, South ... Silicon Biosys­tems Menarini and Macrogen, Inc. today announced ... assays and innovative procedures for precision medicine in ... combine Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s ... of tests certified under the Clinical Laboratory Improvement ...
(Date:2/12/2016)... LOUISVILLE, Ky. , Feb. 12, 2016 ... it has completed a $47.1 million Series ... investors Cormorant Asset Management, Hillhouse Capital Group ... investors Morningside Venture Investments, AJU IB Investment, ... will be used to further advance clinical ...
(Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
Breaking Medicine Technology: